The effect of exacerbation history on outcomes in the IMPACT trial

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The GOLD Science Committee Report 2019

(2019) Dave Singh et al.   EUROPEAN RESPIRATORY JOURNAL

Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial

(2019) Steven Pascoe et al.   Lancet Respiratory Medicine

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study

(2018) Alberto Papi et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

(2018) Alberto Papi et al.   LANCET

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

(2018) David A. Lipson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study

(2018) Claus Vogelmeier et al.   International Journal of Chronic Obstructive Pulmonary Disease

Blood eosinophil counts as a guide for COPD treatment strategies

(2018) Nicolas Roche et al.   Lancet Respiratory Medicine

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials

(2018) Mona Bafadhel et al.   Lancet Respiratory Medicine

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

(2018) Gary T Ferguson et al.   Lancet Respiratory Medicine

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids

(2018) Salman H Siddiqui et al.   International Journal of Chronic Obstructive Pulmonary Disease

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial

(2017) Jørgen Vestbo et al.   LANCET

Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort

(2017) MeiLan K Han et al.   Lancet Respiratory Medicine

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol

(2016) Steven J. Pascoe et al.   EUROPEAN RESPIRATORY JOURNAL

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

(2016) Dave Singh et al.   LANCET

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

(2016) Jadwiga A. Wedzicha et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hospitalized Exacerbations of COPD

(2015) Hana Müllerova et al.   CHEST

Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD

(2015) Ian D Pavord et al.   THORAX

Minimum clinically important difference for the COPD Assessment Test: a prospective analysis

(2014) Samantha S C Kon et al.   Lancet Respiratory Medicine

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

(2010) John R. Hurst et al.   NEW ENGLAND JOURNAL OF MEDICINE